CellSource Co., Ltd. (JP:4880) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CellSource Co., Ltd. will commence consolidated financial reporting starting from the fiscal year ending October 31, 2025, following the establishment of its subsidiary, Hybrid Medical Co., Ltd. The company has released its financial forecasts, projecting net sales of 4,501 million yen and a profit of 255 million yen for the upcoming fiscal year. These forecasts include the anticipated performance of Hybrid Medical.
For further insights into JP:4880 stock, check out TipRanks’ Stock Analysis page.